FDA approves combo eye drop for glaucoma

U.S. regulators approved a new glaucoma treatment—Combigan, an eye drop that treats the potentially blinding eye condition with two drugs that work through different mechanisms, Allergan Inc said Wednesday.

Allergan, best known for its Botox anti-wrinkle drug but is also a leading provider of eye medications and products, said its new drug would be introduced in the fourth quarter of 2007.

The company said Combigan would combine “two strong agents in one bottle”—brimonidine and timolol—to control pressure within the eye that can harm the optic nerve.

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

New biomarkers may influence drug design and alternative treatments of cancer, study shows   UGA ecologist finds another cause of antibiotic resistance   New drug for neuroblastoma shows promise in phase I study   Baclofen shows promise in patients with alcohol-induced liver disease   Joslin researchers find drugs are effective for diabetic macular edema in new trial   Findings point to an ‘off switch’ for drug resistance in cancer   Stopping statins may benefit terminally ill patients   Cholesterol drug users may use pills as a license to overeat   Pfizer lung cancer drug beats chemo for previously untreated patients   Mass. General study identifies path to safer drugs for heart disease, cancer   Gates Foundation awards Notre Dame $23 million for malaria, dengue studies   In the blink of an eye